# Qing Zhou

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/qing-zhou/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,953 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 60 |
| i10-index | 174 |
| Last Known Institution | Jiangnan University |
| OpenAlex ID | https://openalex.org/A5089732639 |
| ORCID iD | 0000-0002-0478-176X |
| Works | 522 |

## Researcher papers

Showing 12 of 23.

- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma](https://scholariq.org/papers/potential-predictive-value-of-i-tp53-i-and-i-kras-i-mutation-status-for-response/)
- [Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study](https://scholariq.org/papers/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii/)
- [EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer](https://scholariq.org/papers/egfr-mutation-correlates-with-uninflamed-phenotype-and-weak-immunogenicity/)
- [Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (<i>ALK</i>) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment](https://scholariq.org/papers/optimizing-the-detection-of-lung-cancer-patients-harboring-anaplastic-lymphoma/)
- [Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy](https://scholariq.org/papers/unique-genetic-profiles-from-cerebrospinal-fluid-cell-free-dna-in-leptomeningeal/)
- [Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations](https://scholariq.org/papers/leptomeningeal-metastases-in-patients-with-nsclc-with-egfr-mutations/)
- [Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression](https://scholariq.org/papers/fusion-of-eml4-and-alk-is-associated-with-development-of-lung-adenocarcinomas/)
- [Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial](https://scholariq.org/papers/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii-2/)
- [Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study](https://scholariq.org/papers/erlotinib-versus-gemcitabine-plus-cisplatin-as-neoadjuvant-treatment-of-stage/)
- [Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma](https://scholariq.org/papers/single-cell-transcriptome-analysis-revealed-a-suppressive-tumor-immune/)
- [Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/relative-abundance-of-i-egfr-i-mutations-predicts-benefit-from-gefitinib/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Jiangnan University](https://scholariq.org/institutions/jiangnan-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.